6/3/2013 7:16:56 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
BerGenBio AS, an emerging oncology biopharma company, has presented data on the importance of the receptor tyrosine kinase, Axl, in acute myeloid leukemia (AML) at the ASCO Annual Meeting 2013, in Chicago, IL. The research, completed by a team led by Dr Sonja Loges from the University Hospital Hamburg-Eppendorf, suggests that Axl represents a novel prognostic marker and potential therapeutic target in AML.
Help employers find you! Check out all the jobs and post your resume.
comments powered by